AlphaStocks
4.9
Weak

Corcept Therapeutics Inc (CORT)

As of Sep 20, 2026, Corcept Therapeutics Inc (CORT) scores 4.9/10 on AlphaStocks' five-model composite, #116 of 168 Health Care stocks.

Health Care / Pharmaceuticals

S&P SmallCap 600

$110.35

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#116out of 168 in Health Care

Is CORCEPT THERAPEUTICS INC a Good Investment in 2026?

CORCEPT THERAPEUTICS INC (CORT) scores 4.9 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model is the most favorable, rating CORCEPT THERAPEUTICS INC as Neutral. However, the Graham model rates it Caution — Significantly above fair value. CORCEPT THERAPEUTICS INC ranks #116 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E132.9ROE10.5Market Cap12B

Valuation

Trades at 133x earnings — significantly above sector median of 30x. Premium reflects market growth expectations.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 2.6 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is CORCEPT THERAPEUTICS INC (CORT) a good investment?
As of Sep 20, 2026, Corcept Therapeutics Inc (CORT) scores 4.9/10 on AlphaStocks' five-model composite, #116 of 168 Health Care stocks. That score is below average, suggesting caution. Trades at 133x earnings — significantly above sector median of 30x. Premium reflects market growth expectations.
What is CORCEPT THERAPEUTICS INC's Piotroski F-Score?
CORCEPT THERAPEUTICS INC's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is CORT overvalued or undervalued?
A precise fair value estimate is not available for CORT. Trades at 133x earnings — significantly above sector median of 30x. Premium reflects market growth expectations.
How does CORT compare to other Health Care stocks?
CORCEPT THERAPEUTICS INC ranks #116 out of 168 stocks in the Health Care sector, placing it in the top 69% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about CORT?
AlphaStocks evaluates CORT using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Caution; Lynch: Neutral. These models are combined into a single composite score of 4.9/10.

Similar Stocks

AMPHLLYACAD

Compare CORT with

AMPH vs CORTCORT vs LLYACAD vs CORTCORT vs VALCORT vs PARR

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer